Amivantamab plus Chemotherapy: New Standard for EGFR Exon 20–Mutated NSCLC

Amivantamab monotherapy has been approved for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) with EGFR exon 20 insertions who have had disease progression after platinum-based chemotherapy. In the industry-supported, international, randomized, phase 3 PAPILLON trial, researchers compared first-line therapy with amivantamab plus platinum-based chemotherapy versus chemotherapy alone in 308 patients with EGFR exon 20 insertion–mutated advanced NSCLC.

Amivantamab was given weekly for 4 weeks then every 3 weeks until disease progression. Chemotherapy consisted of carboplatin and pemetrexed given for 4 cycles followed by maintenance pemetrexed given every 3 weeks until disease progression.

At a median follow-up of 14.9 m…